IMPAC Medical Systems Expands European Radiation Oncology Business

LONDON, Oct. 21 /PRNewswire-FirstCall/ -- IMPAC Medical Systems, , a leading provider of information technology solutions for oncology care, announced today multiple new radiation oncology installations throughout the United Kingdom and Europe. Since expanding its direct operations outside of North America in 2002, the benefits of IMPAC's comprehensive practice management and image-enabled electronic patient record system have become recognized as the industry standard with multiple new installations in prestigious cancer centres throughout the world.

Several recent European radiation oncology installations include Mannheim Medical Center (Mannheim, Germany), Royal Wolverhampton NHS Trust (Wolverhampton, England), North Middlesex University Hospital NHS Trust (London, England), The Christie Hospital NHS Trust (Manchester, England), Trinity College School of Radiotherapy (Dublin, Ireland), Erasmus MC University Medical Center (Rotterdam, The Netherlands), University Medical Centre Utrecht, (Utrecht, The Netherlands), Malar Hospital (Eskilstuna, Sweden), MD Anderson Espana (Madrid, Spain), Hospital CUF Descobertos (Lisbon, Portugal), Institute of Oncology (Ljubljana, Slovenia), and Ege University (Izmir, Turkey).

According to Professor Frederik Wenz, M.D., department of radiation oncology, Mannheim Medical Center, Mannheim, Germany, "When looking for an electronic patient record system we needed to ensure there was full integration with the different makes of radiotherapy equipment used in our facility. The IMPAC system integrated all of our multi-vendor equipment and aggregated critical patient data all into a single, complete picture of patient care that is accessible to our staff wherever and whenever they need it."

IMPAC's comprehensive oncology information system was designed to help radiotherapy centres manage the entire spectrum of critical patient data with process automation tools that improve process efficiencies while reducing the risks of medical error. David Auerbach, president of IMPAC's International Operations, stated, "IMPAC is thrilled that the benefits of our solutions are being recognized on a global level and have proven to improve patient care and enhance provider productivity."

Professor Wenz added, "Prior to IMPAC our department maintained many independent schedules for various resources throughout the clinic. IMPAC has allowed us to combine these schedules into a single system, dramatically improving the clinic's efficiency. Since implementing the IMPAC system, our wait times have been reduced from almost eight weeks to virtually nothing right now."

Ernie Dalton, head of medical physics with the Royal Wolverhampton NHS Trust in Wolverhampton, England, stated "While IMPAC's independent connectivity to linear accelerators, imaging devices, and treatment planning systems allows us the flexibility to integrate best-of-breed hardware, it also allows us to integrate the most modern treatment modalities such as MLC and IMRT treatments directly with the electronic patient record. Further, it allows us the freedom to consider integrating future emerging modalities regardless of vendor."

IMPAC was founded in 1990 to develop an integrated clinical and administrative management system tailored specifically for cancer care and now has more than 2,500 installations in 56 countries worldwide -- including over half of the top North American cancer centres. IMPAC's oncology information solution is currently the only system available that is scalable to accommodate both radiotherapy and chemotherapy data all through a single application, providing oncologists with a comprehensive view of the critical data needed to maximize patient care.

IMPAC's radiotherapy practice management, imaging, and integrated verify & record solution will be on display at the annual European Society for Therapeutic Radiology and Oncology (ESTRO) meeting in Amsterdam, The Netherlands from October 24 - 28, 2004.

About IMPAC Medical Systems

IMPAC Medical Systems, Inc. is a leading provider of oncology IT solutions that streamline both clinical and business operations to help improve the process of delivering quality patient care. With systems designed for anatomic pathology, medical oncology, radiation oncology, imaging, clinical laboratory, and cancer registry, IMPAC supports the entire team of healthcare professionals who contribute to the care of the cancer patient. Supporting more than 2,500 installations worldwide, IMPAC provides practical solutions that deliver better overall communication, process efficiency and quality patient care. For more information about IMPAC products and services, please call 650-623-8800 or visit http://www.impac.com/.

The statements contained in this press release that are not purely historical are forward looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, including statements regarding the Company's expectations, beliefs, hopes, intentions or strategies regarding the future. Forward looking statements include statements regarding the Company's review of its revenue recognition policies and the estimated impact of the proposed financial restatement of previously report results, possible delisting from The NASDAQ Stock Market, business strategy, timing of, and plans for, the introduction of new products and enhancements, future sales, market growth and direction, competition, market share, revenue growth, operating margins and profitability. All forward looking statements included in this document are based upon information available to the Company as of the date hereof, and the Company assumes no obligation to update any such forward looking statement. Actual results could differ materially from the Company's current expectations. Factors that could cause or contribute to such differences include the Company's ability to expand outside the radiation oncology market or expand into international markets, our inability to recognize revenue from multiple element software contracts where certain elements have been delivered, installed and accepted but other elements remain undelivered, lost sales or lower sales prices due to competitive pressures, the ability to integrate its products successfully with related products and systems in the medical services industry, reliance on distributors and manufacturers of oncology equipment to market its products, changes in Medicare reimbursement policies, the integration and performance of acquired businesses, and other factors and risks discussed in the 10-K/A and other reports filed by the Company from time to time with the Securities and Exchange Commission.

For more information, please contact: Mark Arnold International Marketing Manager IMPAC Medical Systems +44 (0)1784 410 416 pr@impac.com

IMPAC Medical Systems

CONTACT: Mark Arnold, International Marketing Manager of IMPAC MedicalSystems, +44 (0) 1784 410 416, or pr@impac.com

Back to news